Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy for locally advanced cervical cancer
CTR20253623Phase 3Active
- Sponsor
- Chengdu Shengdi
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab in Cervical Cancer (CC), sponsored by Chengdu Shengdi. Started Oct 2025; status: active.
02
Drugs
adebrelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20253623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253623.